Aclaris Therapeutics, Inc. +4,51%. Acosense. -15,67%. Acosense TO 2. -24,77%. Airbnb, Inc. - Class A. +3,24%. ALK-Abelló B A/S. -4,06%. Allarity Therapeutics

Find the latest Aclaris Therapeutics, Inc. (ACRS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

-15,67%. Acosense TO 2. -24,77%. Airbnb, Inc. - Class A. +3,24%.

February 25, 2021. Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update. February 22, 2021. Aclaris Therapeutics to Participate in Upcoming Investor Conferences. Köp aktier i Aclaris Therapeutics Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Aclaris Therapeutics, Inc. operates as a pharmaceutical company.

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions.

For investor related questions, please email. investors@aclaristx.com. Tim Lugo.

Pipeline | Aclaris Therapeutics Inc. Diseases and Conditions. Drug Discovery Pipeline. Drug Discovery. Clinical Trials. Publications.

4,756 Aclaris Therapeutics stock traded up about 33% at $1.97 Wednesday morning, in a 52-week range of $0.70 to $5.37. ALSO READ: BofA Has 4 Solid Cloud and Zero-Trust Cybersecurity Stocks to Buy 2021-04-02 · Aclaris Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $30.38.

$164.83. 4.38. 2.73% Aclaris Therapeutics Inc. $20.96. -0.18. -0.85%. Aclaris Therapeutics, Inc. +4,51%.
Utveckling 7 ap fonden

2021-04-05 WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, recently announced its financial results for the fourth quarter and full year of 2020 and provided a corporate update. © 2021 Aclaris Therapeutics, Inc. All rights reserved.

Aclaris Therapeutics, Inc. Condensed Consolidated Statements of Operations (unaudited, in thousands, except share and per share data) Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019: Revenues: Contract research $ 1,331 $ 983 $ 4,373 $ 3,132 Other revenue 118 Aclaris Therapeutics, Inc. Consolidated Statements of Operations (unaudited, in thousands, except share and per share data) Three Months Ended Year Ended December 31, December 31, 2020 2019 2020 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has completed enrollment in its Phase 2a clinical trial of ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, for the potential treatment of moderate to severe atopic dermatitis 2020-08-02 · View the latest Aclaris Therapeutics Inc. (ACRS) stock price, news, historical charts, analyst ratings and financial information from WSJ. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States.
Aclaris therapeutics

Tim Lugo. Aclaris Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Aclaris Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Aclaris Therapeutics, Inc. or its management.

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. 2021-01-19 Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis WAYNE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has completed enrollment in … Aclaris Therapeutics, Inc., a clinical stage specialty pharmaceutical company, today announced that it has entered into an agreement with the stockholders of … Aclaris Therapeutics, Inc. at 10th Annual SVB Leerink Global Healthcare Conference.